Want to see IDXX full AI Analyst Report?

Idexx Laboratories (IDXX) Stock Forecast & Price Target

2,156 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IDXX Analyst Ratings

Moderate Buy

4 Buy

3 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Idexx

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IDXX Stock 12 Month Forecast

Average Price Target

$703.67

▲(19.42% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Idexx Laboratories in the last 3 months. The average price target is $703.67 with a high forecast of $805.00 and a low forecast of $640.00. The average price target represents a 19.42% change from the last price of $589.25.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"534":"$534","602":"$602","670":"$670","738":"$738","806":"$806"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":805,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$805.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":703.6666666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$703.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":640,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$640.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[534,602,670,738,806],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,537.58,558.1507692307692,578.7215384615384,599.2923076923078,619.863076923077,640.4338461538462,661.0046153846154,681.5753846153846,702.1461538461539,722.7169230769231,743.2876923076923,763.8584615384616,784.4292307692308,{"y":805,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,537.58,550.3558974358974,563.1317948717949,575.9076923076923,588.6835897435898,601.4594871794872,614.2353846153846,627.011282051282,639.7871794871795,652.5630769230769,665.3389743589744,678.1148717948718,690.8907692307691,{"y":703.6666666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,537.58,545.4584615384616,553.3369230769231,561.2153846153847,569.0938461538461,576.9723076923077,584.8507692307693,592.7292307692308,600.6076923076923,608.4861538461539,616.3646153846154,624.243076923077,632.1215384615384,{"y":640,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":542.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":535.54,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":639.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":620.11,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":629.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":728.97,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":676.53,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":639.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":636.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":564.66,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":567.46,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":566.79,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":537.58,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$805.00

Average Price Target$703.67

Lowest Price Target$640.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ryan Daniels

William Blair

―

Buy

―

Reiterated

07/07/26

Analysts' Top Healthcare Picks: Idexx Laboratories (IDXX), RxSight (RXST)

Michael Ryskin

Bank of America Securities

$660

Hold

12.01%

Upside

Reiterated

07/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyadic International (NASDAQ: DYAI) and Idexx Laboratories (NASDAQ: IDXX)

Jonathan Block

Stifel Nicolaus

$675

Buy

14.55%

Upside

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX) and Alcon (NYSE: ALC)

Keith Devas

Jefferies

$792

Buy

34.41%

Upside

Reiterated

05/06/26

Idexx Laboratories (IDXX) Receives a Buy from Jefferies

Erin Wright

Morgan Stanley

$765→$805

Buy

36.61%

Upside

Assigned

05/05/26

Erin Wright Reiterates Buy on Idexx After Earnings Beat, Raised 2026 Outlook, and Lifts Price Target to $805

Andrea Alfonso

UBS

$730→$640

Hold

8.61%

Upside

Assigned

04/28/26

UBS Keeps Their Hold Rating on Idexx Laboratories (IDXX)

Daniel Grosslight

Citi

$650

Hold

10.31%

Upside

Initiated

04/16/26

Idexx Laboratories initiated with a Neutral at CitiIdexx Laboratories initiated with a Neutral at Citi

David Westenberg

Piper Sandler

$775→$750

Hold

27.28%

Upside

Reiterated

02/09/26

Idexx Laboratories price target lowered to $750 from $775 at Piper SandlerIdexx Laboratories price target lowered to $750 from $775 at Piper Sandler

Glen Santangelo

Barclays

$850→$800

Buy

35.77%

Upside

Reiterated

02/05/26

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX), Qiagen (NYSE: QGEN) and InnovAge Holding (NASDAQ: INNV)

Mark Massaro

BTIG

$830→$800

Buy

35.77%

Upside

Reiterated

02/03/26

Idexx Laboratories price target lowered to $800 from $830 at BTIGIdexx Laboratories price target lowered to $800 from $830 at BTIG

Chris Schott

J.P. Morgan

$775

Buy

31.52%

Upside

Reiterated

11/03/25

J.P. Morgan Keeps Their Buy Rating on Idexx Laboratories (IDXX)

Daniel Clark

Leerink Partners

$745→$785

Buy

33.22%

Upside

Reiterated

11/03/25

Idexx Laboratories price target raised to $785 from $745 at LeerinkIdexx Laboratories price target raised to $785 from $745 at Leerink

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ryan Daniels

William Blair

―

Buy

―

Reiterated

07/07/26

Analysts' Top Healthcare Picks: Idexx Laboratories (IDXX), RxSight (RXST)

Michael Ryskin

Bank of America Securities

$660

Hold

12.01%

Upside

Reiterated

07/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyadic International (NASDAQ: DYAI) and Idexx Laboratories (NASDAQ: IDXX)

Jonathan Block

Stifel Nicolaus

$675

Buy

14.55%

Upside

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX) and Alcon (NYSE: ALC)

Keith Devas

Jefferies

$792

Buy

34.41%

Upside

Reiterated

05/06/26

Idexx Laboratories (IDXX) Receives a Buy from Jefferies

Erin Wright

Morgan Stanley

$765→$805

Buy

36.61%

Upside

Assigned

05/05/26

Erin Wright Reiterates Buy on Idexx After Earnings Beat, Raised 2026 Outlook, and Lifts Price Target to $805

Andrea Alfonso

UBS

$730→$640

Hold

8.61%

Upside

Assigned

04/28/26

UBS Keeps Their Hold Rating on Idexx Laboratories (IDXX)

Daniel Grosslight

Citi

$650

Hold

10.31%

Upside

Initiated

04/16/26

Idexx Laboratories initiated with a Neutral at CitiIdexx Laboratories initiated with a Neutral at Citi

David Westenberg

Piper Sandler

$775→$750

Hold

27.28%

Upside

Reiterated

02/09/26

Idexx Laboratories price target lowered to $750 from $775 at Piper SandlerIdexx Laboratories price target lowered to $750 from $775 at Piper Sandler

Glen Santangelo

Barclays

$850→$800

Buy

35.77%

Upside

Reiterated

02/05/26

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX), Qiagen (NYSE: QGEN) and InnovAge Holding (NASDAQ: INNV)

Mark Massaro

BTIG

$830→$800

Buy

35.77%

Upside

Reiterated

02/03/26

Idexx Laboratories price target lowered to $800 from $830 at BTIGIdexx Laboratories price target lowered to $800 from $830 at BTIG

Chris Schott

J.P. Morgan

$775

Buy

31.52%

Upside

Reiterated

11/03/25

J.P. Morgan Keeps Their Buy Rating on Idexx Laboratories (IDXX)

Daniel Clark

Leerink Partners

$745→$785

Buy

33.22%

Upside

Reiterated

11/03/25

Idexx Laboratories price target raised to $785 from $745 at LeerinkIdexx Laboratories price target raised to $785 from $745 at Leerink

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Idexx Laboratories

3 Months

Daniel ClarkLeerink Partners

Success Rate

7/9 ratings generated profit

Average Return

+7.60%

Copying Daniel Clark's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +7.60% per trade.

1 Year

Jonathan BlockStifel Nicolaus

Success Rate

26/34 ratings generated profit

Average Return

+26.37%

Copying Jonathan Block's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +26.37% per trade.

2 Years

Jonathan BlockStifel Nicolaus

Success Rate

25/34 ratings generated profit

Average Return

+57.46%

Copying Jonathan Block's trades and holding each position for 2 Years would result in 73.53% of your transactions generating a profit, with an average return of +57.46% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDXX Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IDXX has received 5 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. IDXX average Analyst price target in the past 3 months is 703.67.

Each month's total comprises the sum of three months' worth of ratings.

IDXX Financial Forecast

IDXX Earnings Forecast

Next quarter’s earnings estimate for IDXX is $3.96 with a range of $3.81 to $4.05. The previous quarter’s EPS was $3.47. IDXX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year IDXX has Performed in-line its overall industry.

IDXX Sales Forecast

Next quarter’s sales forecast for IDXX is $1.20B with a range of $1.19B to $1.21B. The previous quarter’s sales results were $1.14B. IDXX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year IDXX has Performed in-line its overall industry.

IDXX Stock Forecast FAQ

What is IDXX’s average 12-month price target, according to analysts?

Based on analyst ratings, Idexx Laboratories’s 12-month average price target is 703.67.

What is IDXX’s upside potential, based on the analysts’ average price target?

Idexx Laboratories has 19.42% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IDXX a Buy, Sell or Hold?

Idexx Laboratories has a consensus rating of Moderate Buy which is based on 4 buy ratings, 3 hold ratings and 0 sell ratings.

What is Idexx Laboratories’s price target?

The average price target for Idexx Laboratories is 703.67. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $805.00 ,the lowest forecast is $640.00. The average price target represents 19.42% Increase from the current price of $589.25.

What do analysts say about Idexx Laboratories?

Idexx Laboratories’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of IDXX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Idexx Laboratories (IDXX) Stock Forecast & Price Target

IDXX Analyst Ratings

IDXX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Idexx Laboratories

IDXX Analyst Recommendation Trends

IDXX Financial Forecast

IDXX Earnings Forecast

IDXX Sales Forecast

IDXX Stock Forecast FAQ

Detailed List of Analyst Forecasts